Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome

• DOI: 10.1210/jc.2004-0176
• Publication Date: 2005-02-08T01:17:00Z
• Authors: V. Jayagopal; E. S. Kilpatrick; S. Holding; P. E. Jennings; S. L. Atkin
• Keywords: Orlistat; Liter; Homeostatic model assessment

The objective of this study was to evaluate and compare the effect treatment with orlistat vs. metformin on hormonal biochemical features patients polycystic ovarian syndrome (PCOS). Twenty-one Caucasian women PCOS [mean (±sem) age 27 ± 0.9 yr body mass index 36.7 3.3 kg/m2] participated in prospective, randomized, open-labeled study. All subjects had an 8-wk run-in period dietary modification then randomized receive either (500 mg three times daily) or (120 for 3 months. Weight, blood pressure, fasting samples were taken at screening, randomization, completion. Insulin resistance (IR) calculated using homeostasis model assessment (HOMA)-IR method [HOMA-IR = (insulin × glucose)/22.5]. results are expressed as mean sem. When compared baseline, both [93.5 11.5 ng/dl (3.24 0.4 nmol/liter) 114.5 (3.97 nmol/liter), P 0.039] [97.2 (3.37 120.0 8.7 (4.16 0.3 0.048] produced a significant reduction total testosterone. Treatment 4.69% weight (99.0 6.0 94.6 6.1 kg, 0.002), more than by (4.69 1.02%, 0.006). There no seen after group insulin, HOMA-IR, SHBG, any lipid parameters studied. In study, testosterone similar that metformin. Therefore, may prove be useful adjunct PCOS.